FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023282331> ?p ?o ?g. }

• W2023282331 endingPage "e1101" @default.
• W2023282331 startingPage "e1101" @default.
• W2023282331 abstract "Multi-drug resistant falciparum malaria is an important health problem in the Peruvian Amazon region. We carried out a randomised open label clinical trial comparing mefloquine-artesunate, the current first line treatment in this region, with dihydroartemisinin-piperaquine.Between July 2003 and July 2005, 522 patients with P. falciparum uncomplicated malaria were recruited, randomized (260 with mefloquine-artesunate and 262 with dihydroartemisinin-piperaquine), treated and followed up for 63 days. PCR-adjusted adequate clinical and parasitological response, estimated by Kaplan Meier survival and Per Protocol analysis, was extremely high for both drugs (99.6% for mefloquine-artesunate and 98.4% and for dihydroartemisinin-piperaquine) (RR: 0.99, 95%CI [0.97-1.01], Fisher Exact p = 0.21). All recrudescences were late parasitological failures. Overall, gametocytes were cleared faster in the mefloquine-artesunate group (28 vs 35 days) and new gametocytes tended to appear more frequently in patients treated with dihydroartemisinin-piperaquine (day 7: 8 (3.6%) vs 2 (0.9%), RR: 3.84, 95%CI [0.82-17.87]). Adverse events such as anxiety and insomnia were significantly more frequent in the mefloquine-artesunate group, both in adults and children.Dihydroartemisinin-piperaquine is as effective as mefloquine-artesunate in treating uncomplicated P. falciparum malaria but it is better tolerated and more affordable than mefloquine-artesunate (US$1.0 versus US$18.65 on the local market). Therefore, it should be considered as a potential candidate for the first line treatment of P. falciparum malaria in Peru.ClinicalTrials.gov NCT00373607." @default.
• W2023282331 created "2016-06-24" @default.
• W2023282331 creator A5001594287 @default.
• W2023282331 creator A5011597585 @default.
• W2023282331 creator A5029054664 @default.
• W2023282331 creator A5033754121 @default.
• W2023282331 creator A5042073037 @default.
• W2023282331 creator A5047759266 @default.
• W2023282331 creator A5069407898 @default.
• W2023282331 creator A5075090194 @default.
• W2023282331 creator A5084150870 @default.
• W2023282331 creator A5086706223 @default.
• W2023282331 date "2007-10-31" @default.
• W2023282331 modified "2023-10-18" @default.
• W2023282331 title "A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru" @default.
• W2023282331 cites W1569685087 @default.
• W2023282331 cites W1595974425 @default.
• W2023282331 cites W1966834016 @default.
• W2023282331 cites W1970461627 @default.
• W2023282331 cites W1974088677 @default.
• W2023282331 cites W2052262611 @default.
• W2023282331 cites W2116677110 @default.
• W2023282331 cites W2121595359 @default.
• W2023282331 cites W2123129595 @default.
• W2023282331 cites W2147581820 @default.
• W2023282331 cites W2150330391 @default.
• W2023282331 cites W2161917102 @default.
• W2023282331 cites W2163924699 @default.
• W2023282331 cites W2169177655 @default.
• W2023282331 cites W2170452509 @default.
• W2023282331 doi "https://doi.org/10.1371/journal.pone.0001101" @default.
• W2023282331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2040506" @default.
• W2023282331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17971864" @default.
• W2023282331 hasPublicationYear "2007" @default.
• W2023282331 type Work @default.
• W2023282331 sameAs 2023282331 @default.
• W2023282331 citedByCount "45" @default.
• W2023282331 countsByYear W20232823312012 @default.
• W2023282331 countsByYear W20232823312013 @default.
• W2023282331 countsByYear W20232823312014 @default.
• W2023282331 countsByYear W20232823312015 @default.
• W2023282331 countsByYear W20232823312016 @default.
• W2023282331 countsByYear W20232823312017 @default.
• W2023282331 countsByYear W20232823312018 @default.
• W2023282331 countsByYear W20232823312019 @default.
• W2023282331 countsByYear W20232823312020 @default.
• W2023282331 countsByYear W20232823312021 @default.
• W2023282331 countsByYear W20232823312022 @default.
• W2023282331 countsByYear W20232823312023 @default.
• W2023282331 crossrefType "journal-article" @default.
• W2023282331 hasAuthorship W2023282331A5001594287 @default.
• W2023282331 hasAuthorship W2023282331A5011597585 @default.
• W2023282331 hasAuthorship W2023282331A5029054664 @default.
• W2023282331 hasAuthorship W2023282331A5033754121 @default.
• W2023282331 hasAuthorship W2023282331A5042073037 @default.
• W2023282331 hasAuthorship W2023282331A5047759266 @default.
• W2023282331 hasAuthorship W2023282331A5069407898 @default.
• W2023282331 hasAuthorship W2023282331A5075090194 @default.
• W2023282331 hasAuthorship W2023282331A5084150870 @default.
• W2023282331 hasAuthorship W2023282331A5086706223 @default.
• W2023282331 hasBestOaLocation W20232823311 @default.
• W2023282331 hasConcept C126322002 @default.
• W2023282331 hasConcept C197934379 @default.
• W2023282331 hasConcept C203014093 @default.
• W2023282331 hasConcept C2776120307 @default.
• W2023282331 hasConcept C2777199930 @default.
• W2023282331 hasConcept C2777616469 @default.
• W2023282331 hasConcept C2778048844 @default.
• W2023282331 hasConcept C2778059366 @default.
• W2023282331 hasConcept C2778371730 @default.
• W2023282331 hasConcept C2781160685 @default.
• W2023282331 hasConcept C71924100 @default.
• W2023282331 hasConcept C98274493 @default.
• W2023282331 hasConceptScore W2023282331C126322002 @default.
• W2023282331 hasConceptScore W2023282331C197934379 @default.
• W2023282331 hasConceptScore W2023282331C203014093 @default.
• W2023282331 hasConceptScore W2023282331C2776120307 @default.
• W2023282331 hasConceptScore W2023282331C2777199930 @default.
• W2023282331 hasConceptScore W2023282331C2777616469 @default.
• W2023282331 hasConceptScore W2023282331C2778048844 @default.
• W2023282331 hasConceptScore W2023282331C2778059366 @default.
• W2023282331 hasConceptScore W2023282331C2778371730 @default.
• W2023282331 hasConceptScore W2023282331C2781160685 @default.
• W2023282331 hasConceptScore W2023282331C71924100 @default.
• W2023282331 hasConceptScore W2023282331C98274493 @default.
• W2023282331 hasIssue "10" @default.
• W2023282331 hasLocation W20232823311 @default.
• W2023282331 hasLocation W20232823312 @default.
• W2023282331 hasLocation W20232823313 @default.
• W2023282331 hasLocation W20232823314 @default.
• W2023282331 hasLocation W20232823315 @default.
• W2023282331 hasLocation W20232823316 @default.
• W2023282331 hasLocation W20232823317 @default.
• W2023282331 hasLocation W20232823318 @default.
• W2023282331 hasOpenAccess W2023282331 @default.
• W2023282331 hasPrimaryLocation W20232823311 @default.
• W2023282331 hasRelatedWork W1948311135 @default.
• W2023282331 hasRelatedWork W2102940694 @default.

• next